WS #15759
Holding: newest synthesis is 5d 16h old
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab for first-line HER2+ breast cancer. This approval expands Pfizer's oncology portfolio and addresses a significant unmet need, providing a direct revenue catalyst for the company's pharmaceutical division.
Biotech FDA Approval
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab for first-line HER2+ breast cancer. This approval expands Pfizer's oncology portfolio and addresses a significant unmet need, providing a direct revenue catalyst for the company's pharmaceutical division.